Impact of body mass index on retention rates of anti-TNF-alfa drugs in daily practice for psoriasis

Journal of Dermatological Treatment

Volumn 23, Issue 6, 2012, Pages 404-409

  Di Lernia, Vito ^a   Tasin, Laura ^b   Pellicano, Riccardo ^c   Zumiani, Giuseppe ^b   Albertini, Giuseppe ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b SANTA CHIARA HOSPITAL   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

adalimumab; BMI; etanercept; infliximab; obesity

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; BODY MASS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PSORIASIS VULGARIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; BODY MASS INDEX; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OBESITY; PSORIASIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84869461878     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2011.593489     Document Type: Article

References (12)

1. Papp KA. The long-term efficacy and safety of new biologic therapies for psoriasis. Arch Dermatol Res. 2006; 298:7-15. (Pubitemid 43725207)
2. Guibal F, Iversen L, Lluis P, Strohal R, Williams P. Identifying the biologic closest to the ideal to treat chronic plaque psoriasis in different clinical scenarios: Using a pilot multiattribute decision model as a decision-support aid. Curr Med Res Opin. 2009;25:2835-2843.
3. Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011;164: 1091-1096.
4. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, et al. Impact of Body Mass Index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare Project. Dermatology. 2008;217: 365-373.
5. Sakai R, Matsui S, Fukushima M, Yasuda H, Miyauchi H, Miyachi Y. Prognostic factor analysis for plaque psoriasis. Dermatology. 2005;211:103-106. (Pubitemid 41160243)
6. Alwawi EA, Krulig E, Gordon KB. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther. 2009;22:431-440.
7. Schmitt I, Zhang Z, Wozel G, Meurer M, Kirch W. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008;159: 513-526.
8. Brunasso AMG, Puntoni M, Salvini C, Delfino C, Curcic P, Gulia A, Massone C. Tolerability and safety of biological therapies for psoriasis in daily clinical practice: A study of 103 Italian patients. Acta Derm Venereol. 2011; 91:44-49.
9. Noiles K, Vender R. Biologic survival. J Drugs Dermatol. 2009;8:329-333.
10. Papoutsaki M, Talamonti M, Giunta A, Costanzo A, Ruzzetti M, Teoli M, Chimenti S. The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. 2010; 221(Suppl 1):43-47.
11. Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A. Dermatol Ther. 2010;23(Suppl 1):S14YS19.
12. Briot K, Garnero P, Le Henanff A, Dougados M, Roux C. Body weight, body composition, and bone turnover changes in patients with spondyloarthropathy receiving antitumour necrosis factor (alpha) treatment. Ann Rheum Dis. 2005;64:1137-1140. (Pubitemid 41113346)